Baxter Announces FDA Approval of ARTISS Fibrin Sealant for Use in Face-Lift (Facial Rhytidectomy) Procedures

Baxter International Inc BAX announced today that the U.S. Food and Drug Administration has expanded the indication of ARTISS [Fibrin Sealant (Human)] to include adhering tissue flaps during facial rhytidectomy surgery (face-lift). ARTISS is the only premixed, ready-to-use fibrin sealant specifically indicated for tissue adherence in facial rhytidectomy (face-lift) and burn surgeries. It was first approved by the FDA in 2008 to adhere autologous skin grafts to surgically prepared wound beds resulting from burns in adult and pediatric populations one year of age or older. “The use of ARTISS in this indication gives surgeons a useful tool to enable full-surface adherence of tissue flaps during surgery, minimizing areas of dead space, and significantly reducing drainage volumes when compared to standard of care,” said Dr. Thomas Mustoe, Professor, Northwestern University Feinberg School of Medicine.